Treatment of Postoperative Pain After Total Hip Arthroplasty Using Intravenous Lidocaine Infusion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1/PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2008-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will focus on patients undergoing total hip arthroplasty and Loma Linda University Medical Center \& East Campus. These patients will be randomized to receive a low dose lidocaine infusion or placebo, in addition to the patient controlled analgesia pump. These groups will be compared to one another statistically to determine which group shows the safest and most satisfying pain control.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Local Infiltration Analgesia in Total Knee Arthroplasty

NCT03206554

Total Knee Arthroplasty Analgesia

COMPLETED PHASE2

Effect of Local Infiltration Anesthesia With Ropivacaine on Pain After Primary Total Hip Arthroplasty

NCT02359136

Osteoarthritis, Hip

COMPLETED NA

Local Infiltration Analgesia in Bilateral Knee Arthroplasty - Efficacy of Subcutaneous Wound Infiltration With Local Anesthetic

NCT00927225

Pain, Postoperative

COMPLETED PHASE4

Local Infiltration Analgesia With Ropivacaine Versus Placebo in Bilateral Hip Arthroplasty

NCT00864409

Postoperative Pain Hip Arthroplasty

UNKNOWN PHASE4

Fascia Iliaca Block for Post-Operative Pain Control After Total Hip Arthroplasty

NCT02299271

Osteoarthritis of the Hip

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Pain Management After Total Hip Arthroplasty

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group

Patients will receive a Dilaudid PCA in combination with a placebo infusion of normal saline.

Group Type PLACEBO_COMPARATOR

Normal Saline

Intervention Type OTHER

Patients in the control group will be receiving an infusion of normal saline for 24 hours postoperatively.

Lidocaine Group

Patients will be receive a Dilaudid PCA in combination with a continuous Lidocaine infusion.

Group Type EXPERIMENTAL

Lidocaine

Intervention Type DRUG

Patients in the experimental group will be receiving a Lidocaine infusion at 1.33 mg/kg/hr for 24 hours postoperatively.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lidocaine

Patients in the experimental group will be receiving a Lidocaine infusion at 1.33 mg/kg/hr for 24 hours postoperatively.

Intervention Type DRUG

Normal Saline

Patients in the control group will be receiving an infusion of normal saline for 24 hours postoperatively.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult male or female undergoing a total hip arthroplasty Subject is American Society of Anesthesiologists physical status 1, 2, or 3 Subject has voluntarily signed and dated the informed consent document approved by the IRB Be English speaking

Exclusion Criteria

* Age \> 80 years old or younger than 18 years old Congestive heart failure Hepatic insufficiency Neurological disorders Psychiatric disorders Steroid treatment No history of atrial fibrillation Chronic pain disorder with opioid treatment

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes